Tag: Esprit BTK
Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment...
Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the...
Newcastle hospital becomes first in UK to implant Abbott’s Esprit BTK...
The Freeman Hospital in Newcastle has become the first in the UK to implant the Esprit BTK everolimus-eluting resorbable scaffold system (Abbott), a press...
Abbott’s Esprit BTK receives Health Canada approval for treating below-the-knee CLTI
Health Canada has authorised the Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of below-the-knee (BTK) chronic limb-threatening ischaemia (CLTI), Abbott revealed today...
Esprit BTK: Drug-eluting resorbable scaffold poised as first-line therapy for below-the-knee...
This advertorial, sponsored by Abbott, is only available to readers in the USA.
“We now have something on label and FDA approved that...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
Drug-eluting resorbable scaffolds “among most exciting technologies” in treatment of peripheral...
A temporary mechanical support with antiproliferative properties might combine two particular treatment qualities to fill a gap in the treatment armamentarium for peripheral arterial...
